原发性胆汁性肝硬化患者血清抗GP210和抗SP100检测的临床意义*

doi:10.3969/j.issn.1672-5069.2011.02.018

Abstract

Abstract: Objective To explore the clinical significance of serum anti-SP100 and anti-GP210 in diagnosis of patients with primary biliary cirrhosis. Methods Serum anti-GP210 and anti-SP100 were detected in 71 patients with PBC and 47 with autoimmune hepatitis，or AIH/PBC overlap syndrome. Results The positive rates in patients with PBC or with non-PBC were not significantly different；in patients with PBC，the specificities of anti-GP210，anti-SP100 and anti-GP210/anti-SP100 were 40.2%，76.6% and 82.4%，while the sensitivities were 26.8%，11.2% and 10.2%；there was no significant difference in the positive rates of the two antibodies or both in patients with different pathological stage of liver diseases. Conclusions The detection of serum anti-GP210 and anti-SP100 do not improve the diagnosis of patients with PBC.

Key words: Primary biliary cirrhosis, Autoimmune hepatitis, Anti-GP210, Anti-SP100

TANG Yingmei，BAO Weimin，YOU Liying，et al.. Clinical significance of serum anti-SP100 and anti-GP210 detection in diagnosis of patients with primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(2): 132-134.

References

[1] LINDOR KD，GERSHWIN ME，POUPON R，et al. AASLD practice guidelines. Primary biliary cirrhosis[J]. Hepatology，2009，50:291-308.
[2] MURATORI P，MURATORI L，GERSHWIN ME，et al.‘True’ antimitochondrial antibody-negative primary biliary cirrhosis，low sensitivity of the routine assays，or both[J]. Clin Exp Immunol，2004，135:154-158.
[3] ALBERT JC. Autoantibodies as prognostic markers in autoimmune liver disease[J]. Dig Dis Sci，2010，55:2144-2126.
[4] ALVAREZ F，BERG PA，BIANCHI FB，et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol，1999，31:929-938.
[5] CHAZOUILLERSE O，WENDUM D，SERFATY L，et al. Primary biliary cirrhosis autoimmune hepatitis overlap syndrome: clinical features and response to therapy[J]. Hepatology，1998，28:296-301.
[6] CHAPMAN R，FEVERY J，KALL CO，et al. Diagnosis and mangement of primary sclerosing cholangitis[J]. Hepatology，2010，51:660-678.
[7] MURATORI P，MURATORI L，FERRARI R，et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis[J]. Am J Gastroenterol，2003，98:431-437.
[8] WORMAN HJ，COURVALIN JC. Antinuclear antibodies specific for primary biliary cirrhosis[J]. Autoimmun Rev，2003，2:211-217.
[9] MIKIEWICZ P，BUWANESWARAN H，COLTESCU C，et al. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease[J]. Clin Gastroenterol Hepatol， 2009，7:1355-1360.
[10] MURATORI P，MURATORI L，CASSANI F，et al. Anti-multiple nuclear dots（anti-MND）and anti-SP100 antibodies in hepatic and rheumatological disorders[J]. Clin Exp Immunol，2002，127:172-175.
[11] GAO L，TIAN X，LIU B，et al. The value of antinuclear antibodies in primary biliary cirrhosis[J]. Clin Exp Med，2008，8:9-15.
[12] MILKIEWICZ P，BUWANESWARAN H，COLTESCU C，et al. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease[J]. Clin Gastroenterol Hepatol， 2009，7（12）:1355-1360.
[13] NAKAMURA M，KONDO H，MORI T，et al. Anti-gp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J]. Hepatology，2007，45:118-127.
[14] CZAJA AJ，MURATORI P，MURATORI L，et al. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis[J]. Liver Int，2004，24:322-329.
[15] BOGDANOS DP，BAUM H，BUTLER P，et al. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection[J]. Dig Liver Dis， 2003，35:801-805.

Clinical significance of serum anti-SP100 and anti-GP210 detection in diagnosis of patients with primary biliary cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Daowei, Fang Jian, Fan Ling.. Implication of serum IL-21 and chemokine levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2019, 22(6): 844-847.
[2]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[3]	Zhang Junfei, Xu Heming, Song Haiyan, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome:poor diagnostic sensitivity of Paris' criteria in Chinese patients [J]. Journal of Practical Hepatology, 2019, 22(4): 537-540.
[4]	Zhou Yanyi, Yang Can. Efficacy of tripterygium glycosides combined with magnesium isoglycyrrhizinate in treatment of patients with autoimmune hepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 365-368.
[5]	Peng Xiaoyan, Xu Lijuan, Liu Peng, Qi Shuangbao, Sun Yiming. Changes of serum adenosine deaminase levels in patients with autoimmune hepatitis and its correlation to hepatic activity index and response to steroid therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 200-203.
[6]	Lin Lan, Shen Min, Ruan Jianwen.. Expression of programmed death receptor 1 in liver tissue of patients with autoimmune hepatitis and its clinical implications [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 204-207.
[7]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[8]	Xia Geng, Qi Fei, Yang Jinhui.. Predisposing factors to autoimmune hepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 983-986.
[9]	Liu Jinguo, Wang Baokui. Efficacy of Fufangbiejia Ruanganpian and ursodeoxycholic acid combination in the treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 340-343.
[10]	Liu Liangyi, Su Dongyuan. Comparison of clinical and liver pathological features of patients with drug-induced liver injury and autoimmune hepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 463-464.
[11]	Qin Wei, Chen Yuping, Yang Zhao, et al. Expression of transforming growth factor β-1 in liver tissues of patients with primary biliary cirrhosis and its relationship with liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 237-240.
[12]	Chen Xiaojun, Song Yang. Changes of peripheral blood T lymphocyte subsets and efficacy of ursodesoxycholic acid and vitamin D combination in treatment of patients with primary biliary cholangitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 80-83.
[13]	Lei Jing. Observation of silybin and diammonium glycyrrhizinate in the treatment of patients with autoimmune hepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 108-109.
[14]	Tao Mingling, Zhang Shibin, Wu Yanjing, et al.. Non-invasive predictors of esophageal varices in patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 439-442.
[15]	Liu Funa, Liu Jiangkui, Shen Yihui.. Efficacy of ursodeoxycholic acid and prednisolone combination in treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 443-446.